Halozyme Therapeutics | HALO - DEBITO





DEBITO Cambiamento Data
Acadia Pharmaceuticals USD 54.81M 1.48M 2025-09
Agios Pharmaceuticals USD 44.52M 4.24M 2025-09
Alnylam Pharmaceuticals USD 1.31B 11.39M 2025-09
Amarin USD 0 0 2025-03
Amgen USD 54.59B 1.62B 2025-09
Baxter International USD 9.71B 13M 2025-09
Cara Therapeutics USD 0 0 2025-03
Cytokinetics USD 1.2B 338.79M 2025-09
DBV Technologies USD 8.59M 295K 2025-09
Eli Lilly USD 42.51B 2.6B 2025-09
Esperion Therapeutics USD 262.92M 1.76M 2024-09
Halozyme Therapeutics USD 1.51B 1.66M 2025-09
Intrexon USD 0 13.82M 2024-06
Ionis Pharmaceuticals USD 2.33B 1.1B 2025-12
MannKind USD 119.91M 73.09M 2025-09
Minerva Neurosciences USD 0 0 2024-09
Nektar Therapeutics USD 0 0 2022-06
Pfizer USD 60.85B 78M 2025-09
Rigel Pharmaceuticals USD 59.69M 90K 2024-06
United Therapeutics USD 200M 100M 2025-03
Vanda Pharmaceuticals USD 4.96M 4.96M 2024-12